NCT01031550

Brief Summary

The objective is to examine the efficacy of isoflurane (inhaled anesthetic gas) to induce clinically effective preconditioning in patients undergoing elective hepatic surgery.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 10, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 14, 2009

Completed
18 days until next milestone

Study Start

First participant enrolled

January 1, 2010

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2012

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2012

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

December 12, 2013

Completed
Last Updated

March 20, 2017

Status Verified

February 1, 2017

Enrollment Period

2 years

First QC Date

December 10, 2009

Results QC Date

September 16, 2013

Last Update Submit

February 13, 2017

Conditions

Keywords

liver resection for liver disease

Outcome Measures

Primary Outcomes (1)

  • Post Operative Complications Grade IIIb or Greater According to Clavien's Classification Which is a Classification System Used to Grade Surgical Complications

    Post operative complications grade IIIB or greater according to Clavien's classification: IIIb=complication necessitating an intervention under general anesthesia; Grade IV=Life threatening complications requiring ICU management, IV a =single organ dysfunction, IVb=multi-organ dysfunction; V=death Suffix d(disability)=subject suffers from complication at time of discharge. This label indicates the need for a follow up to fully evaluate the complication.

    first 7 post operative days

Secondary Outcomes (3)

  • Peak Postoperative AST, ALT and T Bili

    first 7 post operative days

  • Length of ICU and Hospital Stay

    first 7 post operative days

  • Decrease in Liver Lipid Peroxidation and Apoptosis

    first 7 post operative days

Study Arms (2)

standard anesthetic management

ACTIVE COMPARATOR

standard anesthetic management with propofol 100-150mcg/kg/min

Drug: propofol

preconditioning with 2 MAC isoflurane group

EXPERIMENTAL

After induction, anesthesia will be maintained with 1MAC (minimum alveolar concentration) of Isoflurane according to age and end-expiratory concentration. Thirty minutes before the anticipated inflow occlusion and commencement of liver transaction, Isoflurane concentration will be gradually increased to 2 MAC over a period of 5 minutes (induction) and maintained at 2 MAC for 10 minutes (preconditioning). Then the concentration of Isoflurane will be decreased to 1 MAC during next 15 minutes (washout).

Drug: isoflurane

Interventions

isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC

preconditioning with 2 MAC isoflurane group

standard of care

Also known as: diprivan
standard anesthetic management

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with liver tumors undergoing liver resection of \> 1 segment liver resection must be performed with inflow occlusion \> 30 min

You may not qualify if:

  • patients undergoing liver resection of one segment or less
  • patients undergoing laparoscopic liver resection
  • patients in whom the liver resection is performed with no inflow occlusion or inflow occlusion of \< 30 min

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UMDNJ-University Hospital

Newark, New Jersey, 07101, United States

Location

MeSH Terms

Conditions

Liver Diseases

Interventions

IsofluranePropofol

Condition Hierarchy (Ancestors)

Digestive System Diseases

Intervention Hierarchy (Ancestors)

Methyl EthersEthersOrganic ChemicalsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Limitations and Caveats

Due to termination of the study no data analysis was performed.

Results Point of Contact

Title
Yuriy Gubenko, MD
Organization
UMDNJ

Study Officials

  • Yuriy Gubenko, MD

    Rutgers, The State University of New Jersey

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Investigator Intiated Dept of Anesthesia

Study Record Dates

First Submitted

December 10, 2009

First Posted

December 14, 2009

Study Start

January 1, 2010

Primary Completion

January 1, 2012

Study Completion

June 1, 2012

Last Updated

March 20, 2017

Results First Posted

December 12, 2013

Record last verified: 2017-02

Data Sharing

IPD Sharing
Will not share

Locations